|
Myron Arlen
|
| Title: |
Chairman |
| Industry: |
Biotechnology |
| Type of Organization: |
Biotechnology Company |
| Major Product/Service: |
Clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer |
| Expertise: |
Dr. Arlen has over 50 years experience. Having founded his company in 2003, he currently conducts clinical trials through Duke and Johns Hopkins Universities. |
| Geographic Area of Distribution: |
National |
| Affiliations: |
Society of Surgical Oncology; American Association for Cancer Research; Association for Clinical Oncology |
| University/Degree: |
M.D., SUNY Downstate, 1957 |
| Born: |
January 27, 1932, Brooklyn, New York |
| Work History: |
Dr. Arlen previously served as a cancer surgeon and was Chief Resident at Sloan Kettering Memorial Hospital and was involved in the surgery of advanced cancer problems and the immunotherapeutic approaches to managing the patients. In 1990, he worked with the National Cancer Institute and George Washington University to develop cancer vaccines that doubled and tripled survival rates for patients. |
| Published Works: |
2 major textbooks; Published 80+ journal articles related to cancer treatment |
